Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preliminary placebo-controlled evidence paved the ground to the US Food and Drug Administration approval extension of lisdexamfetamine for the treatment of moderate-to-severe binge eating disorder (BED) in adults. OBJECTIVES: To provide a preliminary qualitative and quantitative synthesis of the placebo-controlled, randomized clinical trials (RCTs) considering the efficacy and tolerability of lisdexamfetamine in the acute and/or maintenance treatment of moderate-to-severe BED in adults. METHODS: A preliminary, yet comprehensive, systematic review was performed by accessing a broad range of resources providing publicly available data about lisdexamfetamine at the time of inquiry (March 2016). Study eligibility criteria, participants, and interventions were considered focusing on major clinical and functional outcomes of either efficacy or tolerability of lisdexamfetamine in the treatment of moderate-to-severe BED in adults. RESULTS: Meta-analysis of data pooled from three acute RCTs significantly favored lisdexamfetamine over placebo in the reduction of binge eating days/week, Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating total score, weight, response, and remission rates (all, P≤0.01). In contrast, discontinuation rates due to treatment-emergent adverse events were significantly higher among patients in receipt of lisdexamfetamine (relative risk 2.19, P=0.04) versus placebo. LIMITATIONS: Publication, selection, performance, attrition, reporting, sponsorship, and "diagnostic shift" biases. Lack of inclusion of adverse event effects other than those requiring discontinuation of the trial(s), as well as lack of information about clinically relevant psychiatric or other medical comorbidities, limits the overall generalizability of pooled results. CONCLUSION: Across the included acute phase RCTs, lisdexamfetamine (at 30, 50, or 70 mg/day) led to significant reduction in a number of clinically relevant outcomes compared to placebo. Moreover, safety concerns related to adverse events, high discontinuation rates, and the need for additional long-term maintenance of RCTs solicit careful monitoring of the drug in terms of overall safety and tolerability by further RCTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282 · cited 1×
“49 Specifically, the present systematic review actually included three homogenous acute-treatment studies and one additional maintenance study.”
Kessler, R. C., Berglund, P. A., Chiu, W. T., Deitz, A. C., Hudson, J. I., Shahly, V., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Benjet, C., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.020 · Cited by 1,338
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Davey, J., Turner, R. M., Clarke, M. J., & Higgins, J. P. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-160 · Cited by 404 · cited 1×
“…a preliminary meta-analytic report, even when accounting for heterogeneous active compounds in the same class of drugs and/or differential doses, 47 whereas those meta-analysis accounting for substantially heterogeneous compounds and/or based on incomplete sources would not be informative, not…”
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2162 · Cited by 322 · cited 6×
“Moreover, the FDA extended approval based on two Phase III studies 39 and one Phase II study 38 sharing similar entry criteria, all indicating superiority of lisdexamfetamine over placebo, 23,40 as confirmed by pre-liminary number needed to treat and to harm data computed owing to the primary…”
InfluentialMcElroy, S. L., Hudson, J., Ferreira-Cornwell, M. C., Radewonuk, J., Whitaker, T., & Gasior, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.275 · Cited by 254 · cited 4×
“Moreover, the FDA extended approval based on two Phase III studies 39 and one Phase II study 38 sharing similar entry criteria, all indicating superiority of lisdexamfetamine over placebo, 23,40 as confirmed by pre-liminary number needed to treat and to harm data computed owing to the primary…”
InfluentialStriegel-Moore, R. H., & Franko, D. L. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.4.022007.141149 · Cited by 146 · cited 1×
“Although our search strategy accounted for results indexed from inception until the writing time (March 2016), special emphasis was placed by two appointed authors (MF and LO) on those results indexed since January 2008, as these latter would reflect the recent DSM-5’s introduction of BED as an autonomous disorder, fo…”
Find Duplicates among the PubMed, EMBASE, and Cochrane Library Databases in Systematic Review
Qi, X., Yang, M., Ren, W., Jia, J., Wang, J., Han, G., & Fan, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071838 · Cited by 98
Pharmacological management of binge eating disorder: current and emerging treatment options
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s25574 · Cited by 74 · cited 1×
“…limitations such as small sample size, high placebo response and/or dropout rates, and limited generalizability of findings to real-world practice, 18,19 with no conclusive advantage documented for any drug over alternative approaches, especially dietary, or cognitive behavioral therapy, just to…”
Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine
Guerdjikova, A. I., Mori, N., Casuto, L. S., & McElroy, S. L. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s80881 · Cited by 40 · cited 2×
“…two Phase III studies 39 and one Phase II study 38 sharing similar entry criteria, all indicating superiority of lisdexamfetamine over placebo, 23,40 as confirmed by pre-liminary number needed to treat and to harm data computed owing to the primary outcome “binge-eating days/week” of…”
Cited by
Treasure, J., Duarte, T. A., & Schmidt, U. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30059-3 · Cited by 1,026
Meta-analysis of the efficacy of psychological and medical treatments for binge-eating disorder
Hilbert, A., Petroff, D., Herpertz, S., Pietrowsky, R., Tuschen-Caffier, B., Vocks, S., & Schmidt, R. (2019) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000358 · Cited by 283
Treatment of eating disorders: A systematic meta-review of meta-analyses and network meta-analyses
Monteleone, A. M., Pellegrino, F., Croatto, G., Carfagno, M., Hilbert, A., Treasure, J., Wade, T., Bulik, C. M., Zipfel, S., Hay, P., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104857 · Cited by 283
Self-citationSolmi, M., Monaco, F., Højlund, M., Monteleone, A. M., Trott, M., Firth, J., Carfagno, M., Eaton, M., De Toffol, M., Vergine, M., et al. (2024) · World Psychiatry · doi:10.1002/wps.21182 · Cited by 274
Self-citationCarbone, E. A., Caroleo, M., Rania, M., Calabrò, G., Staltari, F. A., de Filippis, R., Aloi, M., Condoleo, F., Arturi, F., & Segura-Garcia, C. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-020-00910-x · Cited by 52
Metadata
- Authors
- Fornaro, M., Solmi, M., Perna, G., De Berardis, D., Veronese, N., Orsolini, L., Ganança, L., & Stubbs, B.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 12
- Pages
- 1827-1836
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2495179475
- Cited by
- 37
- References
- 10
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.